BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33420576)

  • 1. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
    Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
    J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents.
    Nozawa-Kobayashi M; Sakuma H; Kanemaru H; Kurokawa A; Soga M; Yamashita M; Niimi K; Kobayashi T
    Oral Maxillofac Surg; 2024 Jun; 28(2):849-857. PubMed ID: 38296902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
    Soutome S; Otsuru M; Hayashida S; Murata M; Yanamoto S; Sawada S; Kojima Y; Funahara M; Iwai H; Umeda M; Saito T
    Sci Rep; 2021 Aug; 11(1):17226. PubMed ID: 34446755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
    Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
    J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
    Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
    J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
    Sobczak-Jaskow H; Kochańska B; Drogoszewska B
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
    [No Abstract]   [Full Text] [Related]  

  • 18. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.
    Sim IeW; Sanders KM; Borromeo GL; Seymour JF; Ebeling PR
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3887-93. PubMed ID: 26241323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.
    Drudge-Coates L; Van den Wyngaert T; Schiødt M; van Muilekom HAM; Demonty G; Otto S
    Support Care Cancer; 2020 Sep; 28(9):4019-4029. PubMed ID: 32307659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents.
    Miles E; Arya R; Sproat C; Patel V
    Br Dent J; 2024 May; 236(9):683-687. PubMed ID: 38730156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.